Abstracts tagged "treatment"

Abstract Number: 1404 • 2019 ACR/ARP Annual Meeting
Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea
Min Jung Kim¹, Anna Shin ², Seonghwan Shin ², You-Jung Ha ³, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ¹ and Eun Ha Kang ³, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Limited data are available on whether patients with rheumatoid arthritis (RA) are treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) according to the current recommendations…
Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez ¹, Naydi Pérez-Ríos ¹, Noelia Rodríguez ¹, Grissel Ríos ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³, Daisuke Kato ³ and Désirée van der Heijde ⁴, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
Abstract Number: 757 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis
Hajime Yoshifuji¹, Haruhito Uchida ², Yoshikazu Nakaoka ³, Takahiko Sugihara ⁴, Mitsuaki Isobe ⁵ and Masayoshi Harigai ⁶, ¹Kyoto University, Kyoto, Japan, ²Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Sakakibara Heart Institute, Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Takayasu arteritis (TAK) occurs at a young age and has a long-term clinical course. Progression of arterial stenosis or dilatation leads to organ dysfunction.…
Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting
Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial
Maxime Verhoeven¹, Janneke Tekstra ¹, Attila Pethö-Schramm ², Michelle Borm ³, Jacob van Laar ¹, Floris Lafeber ¹, Johannes Bijlsma ¹, Johannes Jacobs ¹ and Paco Welsing ¹, ¹UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ²Hoffmann-La Roche, Basel, Basel, Switzerland, ³Roche Nederland BV, Woerden, Netherlands
Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
Abstract Number: 2373 • 2019 ACR/ARP Annual Meeting
Two Decades of Changes in RA Treatment and Disease Outcomes from the United States
Sofia Pedro¹, Alyssa Dominique ², Rebecca Schumacher ¹, Yomei Shaw ¹, Kristin Wipfler ¹, Teresa Simon ³ and Kaleb Michaud ⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb*, Princeton, NJ, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: RA causes significant morbidity and mortality. Over the last two decades, several new medications and strategies for treating RA earlier and more aggressively have…
Abstract Number: 508 • 2019 ACR/ARP Annual Meeting
Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Sakae Tanaka ³, Atsushi Kawakami ⁴, Yeong-Wook Song ⁵, Yi-Hsing Chen ⁶, Mitsuhiro Rokuda ⁷, Hiroyuki Izutsu ⁷, Satoshi Ushijima ⁷, Yuichiro Kaneko ⁷, Yoshihiro Nakashima ⁷, Teruaki Shiomi ⁷ and Emi Yamada ⁷, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³University of Tokyo, Tokyo, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁷Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…
Abstract Number: 766 • 2019 ACR/ARP Annual Meeting
Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica
Akiko Aoki¹, Hiroshi Kobayashi ¹ and Hiroshi Oka ¹, ¹Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan
Background/Purpose: Clinical symptoms of polymyalgia rheumatica (PMR) are improved by low-dose glucocorticoids (GC), but relapses and long-term GC therapy are common. 2015 EULAR/ACR recommendations suggest…
Abstract Number: 1422 • 2019 ACR/ARP Annual Meeting
Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Sean Connolly ⁷, Kuan-Hsiang Gary Huang ⁷, Yedid Elbez ⁸, Sumanta Mukherjee ⁷ and Roy Fleischmann ⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…
Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
Abstract Number: 510 • 2019 ACR/ARP Annual Meeting
Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels
Christina Charles-Schoeman¹, Thierry Sornasse ² and Jeremy Sokolove ², ¹University of California, Los Angeles, CA, ²AbbVie Immunology Clinical Development, Redwood City
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory condition associated with increased rates of atherosclerotic progression via pathogenic remodeling of high-density lipoprotein (HDL)-associated proteins, resulting…
Abstract Number: 785 • 2019 ACR/ARP Annual Meeting
Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience
Muhammad Shipa¹, Anastasia-vasiliki Madenidou ², vera Choida ¹, Anna Radziszewska ³, corinne fisher ⁴, coziana ciurtin ¹, maria Leandro ¹ and Debajit Sen ¹, ¹Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, London, United Kingdom, ²Centre for Adolescent Rheumatology, University College London London, UK, LOndon, ³University College London, London, United Kingdom, ⁴Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, lonodn, United Kingdom
Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
Abstract Number: 1425 • 2019 ACR/ARP Annual Meeting
Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial
Thomas Huizinga¹, René Toes ¹, Michael Weinblatt ², Michael Schiff ³, Roy Fleischmann ⁴, Yedid Elbez ⁵, Sean Connolly ⁶, Michael Maldonado ⁶ and Sheng Gao ⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ³University of Colorado, Denver, CO, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Excelya, Boulogne-Billancourt, France, ⁶Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a marker for early, erosive RA.1 In the Abatacept (ABA) versus adaliMumab (ADA) comParison in bioLogic-naïvE RA subjects with…
Abstract Number: 2380 • 2019 ACR/ARP Annual Meeting
Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome
Toshihisa Kojima¹, Masayo Kojima ², Hajime Ishikawa ³, Sakae Tanaka ⁴, Nobuhiko Haga ⁵, Keiichiro Nishida ⁶, Masao Yukioka ⁷, Jun Hashimoto ⁸, Hisaaki Miyahara ⁹, Yasuo Niki ¹⁰, Tomoatsu Kimura ¹¹, Hiromi Oda ¹², Shuji Asai ¹, Koji Funahashi ¹³ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Nagoya City University Graduate School of Medicne, Nagoya, Japan, ³Niigata Rheumatic Center, Niigata, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵The University of Tokyo Hospital, Tokyo, Japan, ⁶Okayama University, Graduate School of Medicine, Okayama, Japan, ⁷Yukioka Hospital, Osaka, Japan, ⁸National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ⁹National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, ¹⁰Keio University, School of Medicine, Tokyo, Japan, ¹¹University of Toyama, Faculty of Medicine, Toyama, Japan, ¹²Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ¹³Kariya-Toyota General Hosptal, Kariya, Japan
Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. In these days,…
Abstract Number: 513 • 2019 ACR/ARP Annual Meeting
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Josef Smolen¹, Paul Emery ², William Rigby ³, Yoshiya Tanaka ⁴, Juan Ignacio Vargas ⁵, Nemanja Damjanov ⁶, Manish Jain ⁷, Yunxia Sui ⁸, Jose Jeffrey Enejosa ⁹, Aileen Pangan ¹⁰, Heidi Camp ⁹ and Stanley Cohen ¹¹, ¹Medical University of Vienna, Vienna, Austria, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Dartmouth-Hitchcock Medical Center, Lebanon, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Quantum Research, Puerto Varas, Chile, ⁶Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁷Rheumatology, Great Lakes Clinical Trials, Great Lakes, ⁸AbbVie Inc., Chicago, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, ¹¹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK1-selective inhibitor, showed efficacy when used as monotherapy over 14 weeks (wks) in rheumatoid arthritis (RA)…

« Previous Page
1
…
3
4
5
6
7
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].